Clinical Trials Browser

Phase 2/3 × Hematologic Neoplasms × Immunotherapy, Adoptive × Clear all

NCT06238336 2024-02-02

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Phase 2/3 Unknown

Other hematologic neoplasm

Hematologic Neoplasms